389 related articles for article (PubMed ID: 17227708)
1. The role of Shp2 (PTPN11) in cancer.
Mohi MG; Neel BG
Curr Opin Genet Dev; 2007 Feb; 17(1):23-30. PubMed ID: 17227708
[TBL] [Abstract][Full Text] [Related]
2. The tyrosine phosphatase Shp2 (PTPN11) in cancer.
Chan G; Kalaitzidis D; Neel BG
Cancer Metastasis Rev; 2008 Jun; 27(2):179-92. PubMed ID: 18286234
[TBL] [Abstract][Full Text] [Related]
3. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
4. A novel PTPN11 gene mutation in a patient with LEOPARD Syndrome.
Du-Thanh A; Cave H; Bessis D; Puso C; Guilhou JJ; Dereure O
Arch Dermatol; 2007 Sep; 143(9):1210-1. PubMed ID: 17875892
[No Abstract] [Full Text] [Related]
5. Mutations of PTPN11 are rare in adult myeloid malignancies.
Hugues L; Cavé H; Philippe N; Pereira S; Fenaux P; Preudhomme C
Haematologica; 2005 Jun; 90(6):853-4. PubMed ID: 15951301
[TBL] [Abstract][Full Text] [Related]
6. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.
Mohi MG; Williams IR; Dearolf CR; Chan G; Kutok JL; Cohen S; Morgan K; Boulton C; Shigematsu H; Keilhack H; Akashi K; Gilliland DG; Neel BG
Cancer Cell; 2005 Feb; 7(2):179-91. PubMed ID: 15710330
[TBL] [Abstract][Full Text] [Related]
7. Oxidation sensitivity of the catalytic cysteine of the protein-tyrosine phosphatases SHP-1 and SHP-2.
Weibrecht I; Böhmer SA; Dagnell M; Kappert K; Ostman A; Böhmer FD
Free Radic Biol Med; 2007 Jul; 43(1):100-10. PubMed ID: 17561098
[TBL] [Abstract][Full Text] [Related]
8. A novel PTPN11 mutation in LEOPARD syndrome.
Conti E; Dottorini T; Sarkozy A; Tiller GE; Esposito G; Pizzuti A; Dallapiccola B
Hum Mutat; 2003 Jun; 21(6):654. PubMed ID: 14961557
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine phosphatases such as SHP-2 act in a balance with Src-family kinases in stabilization of postsynaptic clusters of acetylcholine receptors.
Camilleri AA; Willmann R; Sadasivam G; Lin S; Rüegg MA; Gesemann M; Fuhrer C
BMC Neurosci; 2007 Jul; 8():46. PubMed ID: 17605785
[TBL] [Abstract][Full Text] [Related]
10. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Chen Y; Takita J; Hiwatari M; Igarashi T; Hanada R; Kikuchi A; Hongo T; Taki T; Ogasawara M; Shimada A; Hayashi Y
Genes Chromosomes Cancer; 2006 Jun; 45(6):583-91. PubMed ID: 16518851
[TBL] [Abstract][Full Text] [Related]
11. Receptor and nonreceptor protein tyrosine phosphatases in the nervous system.
Paul S; Lombroso PJ
Cell Mol Life Sci; 2003 Nov; 60(11):2465-82. PubMed ID: 14625689
[TBL] [Abstract][Full Text] [Related]
12. Identification of protein tyrosine phosphatases and dual-specificity phosphatases in mammalian spermatozoa and their role in sperm motility and protein tyrosine phosphorylation.
González-Fernández L; Ortega-Ferrusola C; Macias-Garcia B; Salido GM; Peña FJ; Tapia JA
Biol Reprod; 2009 Jun; 80(6):1239-52. PubMed ID: 19211810
[TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine phosphatase function: the substrate perspective.
Tiganis T; Bennett AM
Biochem J; 2007 Feb; 402(1):1-15. PubMed ID: 17238862
[TBL] [Abstract][Full Text] [Related]
14. Noonan syndrome type I with PTPN11 3 bp deletion: structure-function implications.
Lee WH; Raas-Rotschild A; Miteva MA; Bolasco G; Rein A; Gillis D; Vidaud D; Vidaud M; Villoutreix BO; Parfait B
Proteins; 2005 Jan; 58(1):7-13. PubMed ID: 15521065
[TBL] [Abstract][Full Text] [Related]
15. Protein tyrosine phosphatases and breast cancer.
Freiss G; Vignon F
Crit Rev Oncol Hematol; 2004 Oct; 52(1):9-17. PubMed ID: 15363463
[TBL] [Abstract][Full Text] [Related]
16. Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia.
Xu R
Cell Res; 2007 Apr; 17(4):295-7. PubMed ID: 17404595
[No Abstract] [Full Text] [Related]
17. Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer.
Laczmanska I; Sasiadek MM
Acta Biochim Pol; 2011; 58(4):467-70. PubMed ID: 22146137
[TBL] [Abstract][Full Text] [Related]
18. Leukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding protein.
Huang W; Saberwal G; Horvath E; Zhu C; Lindsey S; Eklund EA
Mol Cell Biol; 2006 Sep; 26(17):6311-32. PubMed ID: 16914719
[TBL] [Abstract][Full Text] [Related]
19. Hyperactive Ras in developmental disorders and cancer.
Schubbert S; Shannon K; Bollag G
Nat Rev Cancer; 2007 Apr; 7(4):295-308. PubMed ID: 17384584
[TBL] [Abstract][Full Text] [Related]
20. Selective activation of SHP2 activity by cisplatin revealed by a novel chemical probe-based assay.
Kuo CC; Chu CY; Lin JJ; Lo LC
Biochem Biophys Res Commun; 2010 Jan; 391(1):230-4. PubMed ID: 19909727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
